Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Getting access
Committee review Health/Medical/Biomedical (HMB)
- Apply at
- https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003019.v1.p1
- Agreement
- Data use agreement
- Cost
- No charge
- Renewal
- Every 1 year
From the operator’s published policy metadata.
About this database
| Last updated | 2026-09-12 |
|---|